Ant venom immunotherapy in Australia: The unmet need

Raymond J. Mullins; Simon G.A. Brown

doi:10.5694/mja13.00035

Ant venom immunotherapy in Australia: The unmet need

Raymond J. Mullins, Simon G.A. Brown

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.

Original language	English
Pages (from-to)	33-34
Number of pages	2
Journal	Medical Journal of Australia
Volume	201
Issue number	1
DOIs	https://doi.org/10.5694/mja13.00035
Publication status	Published - 7 Jul 2014
Externally published	Yes

Access to Document

10.5694/mja13.00035

Cite this

@article{72f867221c1d4d5cb6460510dc3d31f0,

title = "Ant venom immunotherapy in Australia: The unmet need",

abstract = "Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.",

author = "Mullins, {Raymond J.} and Brown, {Simon G.A.}",

year = "2014",

month = jul,

day = "7",

doi = "10.5694/mja13.00035",

language = "English",

volume = "201",

pages = "33--34",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Co. Ltd",

number = "1",

}

TY - JOUR

T1 - Ant venom immunotherapy in Australia

T2 - The unmet need

AU - Mullins, Raymond J.

AU - Brown, Simon G.A.

PY - 2014/7/7

Y1 - 2014/7/7

N2 - Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.

AB - Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.

UR - http://www.scopus.com/inward/record.url?scp=84904508309&partnerID=8YFLogxK

U2 - 10.5694/mja13.00035

DO - 10.5694/mja13.00035

M3 - Article

SN - 0025-729X

VL - 201

SP - 33

EP - 34

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 1

ER -

Ant venom immunotherapy in Australia: The unmet need

Abstract

Access to Document

Other files and links

Fingerprint

Cite this